Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.

@article{Rocchetti2009TestingAO,
  title={Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.},
  author={Maurizio Rocchetti and Francesca Del Bene and Massimiliano Germani and Francesco Fiorentini and Italo Poggesi and Enrico Pesenti and Paolo Magni and Giuseppe de Nicolao},
  journal={European journal of cancer},
  year={2009},
  volume={45 18},
  pages={3336-46}
}
In clinical oncology, combination regimens may result in a synergistic, additive or antagonistic interaction (i.e. the effect of the combination is greater, similar or smaller than the sum of the effects of the individual compounds). For this reason, during the drug development process, in vivo pre-clinical studies are performed to assess the interaction of anticancer agents given in combination. Starting from a widely used single compound PK/PD model, a new additivity model able to predict the… CONTINUE READING